The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle ...

Rs 1,102.90 apiece. The company reported that its consolidated net profit fell 11.3% on the year to Rs 346 crore in the ...

As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer ...